John Parkinson

A group of personnel at a veterans administration medical center (VAMC)) did a drive-thru to help bolster vaccination amongst coworkers.

Investigators followed patients with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) for 6 months to review their outcomes.

A Swiss population-based study showed more people in socioeconomically challenged places tested positive more frequently, saw higher hospitalizations, and greater mortality rates than those in higher socioeconomic places.

Azithromycin versus standard care in patients with mild-to-moderate COVID-19, did not reduce the risk of hospital admission or mortality.

The company’s RBX2660, administered as a single dose, demonstrated superiority over standard of care for reducing Clostridioides difficile infection (CDI) recurrence.

CDC says infections linked to the consumption of Jule’s Cashew Brie, a vegan, or plant-based cheese alternative, was linked to the cashews used in the ingredients.

A new Australian study shows the infection rate was 1.61 cases per 1000 people per year over a 3 year study period in participants with access to the therapy.

The therapy would be the first capsid inhibitor and the only HIV treatment option administered every 6 months.

The Food and Drug Administration (FDA) said the company is concerned about cyclospora contamination on the company’s Dole Fresh Blueberries brand.

A study looked at the prevalence of Metallo-B-lactamase (MBLs) producing A. baumannii isolates in one hospital setting.

The newly approved therapy will use the brand name, Brexafemme, and is a one-day, novel, oral treatment for vaginal yeast infection.

Sensors provided data for more hand washing opportunities for healthcare workers and affected related behaviors.

During the pandemic, one regional health system looked at the age distribution of the virus and hospitalization and mortality rates.

With a small number of heart-related adverse effects in younger people, the US Food and Drug Administration (FDA) will move towards a warning statement for Pfizer and Moderna vaccines.

Regeneron’s monoclonal antibodies, casirivimab and imdevimab (REGEN-COV), reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response.

This mutation also known as B.1.617.2, and first discovered in India is making its way westward and is an emerging infection in the US.

With the company reporting its data today and it applying for authorization with regulatory bodies internationally, and later this year with the US Food and Drug Administration (FDA), what does the prospect of this new vaccine mean to people in the US and internationally?

Cartesian Therapeutics has created its therapy, Descartes-30, the first RNA cell therapy for acute respiratory distress syndrome (ARDS), and the company is now recruiting for a clinical trial.

The federal agency has asked Johnson & Johnson to discard its COVID-19 vaccine made at a plant in Baltimore.

The committee members discussed their concerns about having sufficient data to make an informed decision around the risk vs. benefits for looking at potential FDA approvals for vaccines in this population group.

The company’s submission is for teens 12-17 years old and is based on data from its phase 2/3 trial studying its mRNA-1273 vaccine.

The mutation, first identified in India, has been growing here and is disproportionately affecting younger people in the UK. The CDC and the Biden Administration continue to express the importance of vaccination as a way to combat the strain.

In a population-based cohort study with a mean follow-up of 3.6 years, childhood outcomes showed no statistically significant associations with any adverse health conditions.

The company recently began its phase 2/3 trial for its investigational therapy.

With the US Centers for Disease Control and Prevention's recent change to mask guidance for vaccinated people, some confusion ensued and left state governments and businesses scrambling to react to the update.

The government agency will be assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine.

This is the first oral non-azole treatment for vaginal yeast infections.

If it is approved, this would be the first new antifungal class in the United States in years.

During the COVID-19 surge last year, the federal government stopped the required reporting on healthcare-associated infections (HAI) thus leaving an absence of data and important information on HAI. One study examined the effect the initial pandemic surge had on Clostridioides Difficile infection (CDI) in one hospital.

Do the very freedoms Americans enjoy allow us to make less than optimal choices? And will it prevent us from doing what medical science says is best if needed again?